The rat tyrosine aminotransferase (TAT) gene promoter (nucleotides -350 to +1; TAT 0 35 ) was able to sustain liver-specific expression both ex vivo in transient transfection (TAT-expressing H4IIEC3 hepatoma cells vs. TAT non-expressing CCL1.2 fibroblasts) and in in vitro transcription (rat liver vs. spleen crude nuclear extracts). In either case, the index of tissue specificity (6.2 and 6.7 in ex vivo and in vitro experiments, respectively) was close to that obtained with 10 Kb of TAT gene 5'-flanking sequences in transient transfection. Using computer-assisted search of homologies, DNase I footprinting, gel retardation and methylation interference assays, we showed that TAT 0 35 sequences spanning nt -156 to -175 and nt -268 to -281 interacted with the liver enriched NF-1 Liver (a member of the NF1 gene family) and HNF1 respectively, whereas those encompassing nt -57 to -85 and nt -283 to -288 interacted with the ubiquitous NF-Y and with ubiquitous 'CCAAT'-box binding factor(s), respectively. Competition studies in in vitro transcription carried out with wild type and mutated oligonucleotides, demonstrated that NF-Y ciselements were crucial for basal TAT promoter activity, both in liver and spleen whereas NF1 Liver and HNF1 were only efficient in the liver (supported -60% and 30% of basal TAT0.35 activity respectively). Altogether, these results support the conclusion that TAT 03s was able to sustain at least part of the liver specificity of TAT gene expression.
INTRODUCTION
Constitutive expression of several liver-specific genes has been shown to be driven by a few hundred nucleotides (up to 500) of 5'-flanking sequences, this basal promoter activity being often enhanced or repressed (extinguished) by either constitutive or hormone-dependent far upstream sequences (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
In the liver, the tyrosine aminotransferase (TAT) gene belongs to the genes' cluster that is activated in the neonatal period (reviewed in 12). Thereafter, TAT gene expression is modulated by hormones such as glucagon (via the cAMP signaling pathway; 13, 14) and glucocorticoids (15; review in 16).
Constitutive and hormone-induced TAT gene expression is dependent on at least two distinct genetic loci (17) (18) (19) ; see 20 for review). One of these loci (Tse-1) extinguishes basal TAT gene expression, but leaves the gene partially responsive to glucocorticoids (19) , consistent with previous studies of the extinction phenomenon in intertypic somatic cell hybrids (18, 21) . Making use of Tse-1 -containing or non-containing and of FTO2B hepatoma cells, Boshart and coworkers (22) have shown that one motif (BI), which maps -3.6 Kb 5' to the TAT cap site and encompasses a cAMP response element (TAT-CRE), was the primary target for 7ie-7-mediated gene extinction. A nearby motif, Bin, which binds the liver-enriched rra/w-acting factor HNF4, cooperates with the TAT-CRE, and confers a strong liverspecificity to the -3.6 Kb enhancer (23) .
The -3.6 Kb enhancer lies within a DNAse I hypersensitive site (HS). Seven such HSs have been mapped within 11 kb of TAT gene 5'-flanking sequences both in liver and in hepatoma cells (24) (25) (26) . Most of these HSs are constitutive, and behave as liver-specific enhancers acting on either basal (26) or glucocorticoid-induced (25) transcription. A single HS is hormone-dependent and is responsible for primary glucocorticoid induction (27) .
One of these HSs, the promoter-HS was different (absence of the distal cleavage at -200) in Tse-1 positive versus Tse-1 negative hepatoma cell lines (23, 26) . This observation suggested that the TAT promoter itself might be involved in the liverspecific control of TAT gene expression and prompted us to address the following questions: (a) are proximal TAT gene *To whom correspondence should be addressed + Presem address: INSERM U142, Hdpital Saint Antoine, 75571 Paris Cedex 12, France 5'-flanking sequences able to drive basal liver-specific gene expression and (b) is this tissue-specificity due to the presence of rra/is-acting factors in TAT-producing cells or alternatively to that of trans-acting repressor(s) in TAT non expressing cells?
In the present paper, we provide evidence that TAT promoter sequences (nt -350 to +1) are able to sustain liver-specific expression, both in transient transfection and in in vitro transcription, and that two liver-enriched trans-acting factors, NFl Liver and HNF1 and the ubiquitous NF-Y contribute to liverspecific transcription from the TAT promoter. Their respective role in the tissue-specificity is discussed.
MATERIALS AND METHODS

Transient expression and transcription vectors
pSV E CAT, the promoterless pSBl and pTC, 0 expression vectors have been described elsewhere (28, 29) . pTC 3 3 was obtained by HindlH digestion and subsequent recircularization of pTCi 0 . Conversion of the unique Kpnl site of pTC 10 into a Hindin site, followed by complete HindlH digestion and recircularization, yielded pTC O 3 5 . In pTC 10 , pT-C3 3 and pTCo.35, transient CAT expression was driven by TAT gene 5'-flanking sequences spanning from nt -10,095, -3,336 and -350 to nt +3 respectively (Fig.lA) . The additional pT-C 9 , pTC 3 9, pTC 3 , pTC| 3 were generated from pTC 10 , making use of Smal (-8,923), Xhol (-3,918), EcoRI (-3,046) and BamHI (-1,299) restriction sites, respectively.
The DNA templates used in in vitro transcription p(C2AT)]g, pML(C 2 AT), 9 (referred to as pAdML^,) (30) or pAdMI^vo (9) , and pTAT generated G-free transcripts of 385bp (pAdML 37O ), 375bp (pTAT) or 270bp (pAdMLjvo). pTAT and pTAT inv corresponded to insertions of a 394bp SstI fragment excised from pTCo 35 either in the correct or reverse orientation relative to the 'G-free cassette', respectively (Fig.IB) .
Plasmid DNA was prepared and purified according to (31) and (32) .
Cell culture and transient transfection
Differentiated rat hepatoma cells H4IIEC3 (H4II herein) (33) and mouse fibroblasts L-M (ATCC CCL1.2) were cultured in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum (34) and in Dulbecco's modified Minimum Essential Medium supplemented with 10% fetal calf serum, respectively.
Transfection (20 /tg of plasmid DNA/dish) was carried out using the calcium phosphate-DNA co-precipitation procedure (35), as described (1, 36) and cells were harvested 72 h posttransfection. For each construct, a minimum of 3 independent transfection experiments were performed wirn at least 2 different plasmid preparations.
CAT assays
CAT activity (37) was assayed as in (1) (100 /ig total protein/ assay; 37°C for 1-3 h) and normalized as follows:
CAT activity expressed from the test plasmid per pmol of transfected test plasmid CAT activity expressed from pSV E -CAT per pmol of transfected pSV E -CAT Tissue-specific index was calculated as follows:
normalized CAT activity in H4II normalized CAT activity in L-M Nuclear extract preparation and in vitro transcription reaction Rat (10-11 week-old male Sprague-Dawley) liver and spleen crude nuclear extracts (CNEs) (2) were always prepared in the presence of protease inhibitors (38, 39) . Transcription was carried out according to Gorski et al. (2) . The transcription mixtures (20 /il) contained 2.4 mg/ml of liver or spleen nuclear proteins, 0.4 mM of 3'-O-methyl GTP (Pharmacia), and template DNA: 5-40 /ig/ml of pAdML 370 or pTAT in dose-response experiments; 30 jig/ml of pTAT and 10 ftg/ml of linearised pAdML2 7 o in competition experiments.
Following transcription, the reaction mixture was treated with proteinase K, extracted with phenol-chloroform, precipitated with ethanol and the radioactive transcripts were analysed on sequencing gels (7 M urea-4% acrylamide). Bona fide transcripts were quantitated eidier by liquid scintillation counting of the dried gel, or by laser densitometry scanning of the gels' autoradiograms, within the linear range of the film's response (GelScan; LKB). Protein -DNA binding assays DNAse I protection assays (40) were performed as described (38) . 32 P-end-labeled TAT O35 (50ng/ml) was mixed with double stranded poly (dl-dC) (50 /tg/ml) and incubated at 0°C for 15 min either with BSA (1 mg/ml; control) or with liver or spleen CNEs (0.5-1 mg protein/ml) in a final volume of 20 jtl. DNase I (Cooper Biomedical) was then added at either 1.25 /ig/ml (control) or 2.5 /ig/ml (CNEs) and digestion was allowed to proceed at 0°C for 1-3 min. When digestion was completed, the samples were processed as described (38) and analyzed on sequencing gels (7 M urea-5% acrylamide). The gels were dried and autoradiographed at -70°C.
When gel mobility shift assays (41) were to be performed, the 20 /*1 incubation mixture contained 50ng/ml of 32 P-end-labeled synthetic ds-oligonucleotides, 50/ig/ml of double stranded poly(dl-dC) and 0.3mg/ml of liver or spleen CNEs. After a 10 min incubation at 0°C, the reaction mixture was analyzed on 6% non-denaturating polyacrylamide gels. The gels were then dried and autoradiographed at -70°C. (Table I) . Howewer, whatever the length of 5'-flanking sequences, the magnitude of CAT expression was always significantly higher (p<0.05) in hepatoma cells than in fibroblasts with TS^^ larger than 5 (p<0.05). The slight variations (max. ~35%) in TSjnd,.* observed between constructs were not significant (p>0.5). Moreover, the liver-specificity of basal promoter activity was not dependent on the presence or absence of functional GREs (-2.5 HS). Such was not the case of glucocorticoid-induced CAT expression which was both highly liver-specific and dependent on the presence of -2.5HS (Table I). TAT 0 .3s drives efficient liver-specific in vitro transcription Since TAT 0 .3 5 was able to drive tissue-specific CAT gene expression in differentiated hepatoma cells, we checked whether these promoter elements were also able to drive liver-specific in vitro transcription. Transcription assays (2) were performed as a function of template concentration in the presence of a constant amount of liver or spleen CNEs ( Fig. 2A and 2B ) and the results of 2-7 independent experiments were compiled ( Fig.  2C and 2D) .
RESULTS
The
With rat liver CNEs, the amount of transcripts synthetized from the AdML and TAT 0 35 promoters were almost undetectable when plasmid concentration was 5 /ig/ml ( Fig. 2A, lanes 1,6) . Similar patterns of transcription efficiency were obtained from both promoters as a function of template concentration, with an optimum at -30 /ig/ml of template DNA ( Fig. 2A) . At optimal template concentration, the average amount of bona fide transcripts synthetized from pTAT represented -48% of that synthetized from pAdML (Fig. 2C) . The decrease observed at 40/tg/ml was probably related to exhaustion of ubiquitous transcription factor(s) (Fig. 2C ). Transcripts were never obtained when incubation was carried out in thepresence of 2 jtg/ml aamanitin or of pTAT inv (not shown).
With rat spleen CNEs, the bell-shaped pattern of transcription (similar to those obtained with either pAdML^o or pTAT in the presence of liver CNEs) was only obtained from the AdML promoter (Fig. 2D) . In contrast, TAT 0 35 driven transcription was very weak; very low amounts of transcripts accounting for 7.2% and 13.6% of those synthesized from pAdML at identical template concentrations were generated only at 30 and 40 ng/ml of template, respectively ( Fig. 2B and D) .
Under optimal in vitro transcription conditions with liver and spleen CNEs (30 jtg/ml of template), the tissue specific index equalled 6.7. Although still significant it declined sharply (2.9-fold) at 40 jtg/ml (at DNA concentrations < 30 /xg/ml, the tissue specific index was not computable, due to the lack of TAT 0 35 driven transcription in the presence of spleen CNEs).
The results obtained both in transient transfection and in in vitro transcription experiments led us to propose that the 350 bp of TAT gene 5'-flanking sequences closest to the cap site were able to drive liver-specific gene expression. The TAT0.35 promoter binds ubiquitous and tissue-specific trans-acting factors In vitro footprinting experiments showed that a series of closely spaced TAT 035 sequences were protected from DNAse I digestion. In most cases the patterns of protection displayed in the presence of spleen or liver CNEs were superimposable, although at a given protein concentration, the magnitude of livermediated protection was often weaker (Fig. 3) . In contrast, the protection of the sequence spanning nt -147 to -200 was more efficient in the presence of liver than of spleen CNEs (Fig. 3A , lanes 3-8; Fig. 3B, lanes 2, 3) , and was more obvious on the lower than on the upper strand (compare protections in Fig. 3A and 3C).
Localisation of putative cis-acting elements for ubiquitous and liver-specific fra/is-acting factors within TAT 0 . 35 Ds-oligos encompassing the TAT0.35 sequences that had been shown to be protected in in vitro DNase I footprinting (ds-oligos II-VIE in Table II) were designed. Gel shift assays showed that only the retardation patterns displayed by ds-oligos V, VI, VII and Vm were dependent on the origin of the CNE (not shown), suggesting that the corresponding sequences interacted with at least some tissue-specific factor(s). As a matter of fact, search of homologies pointed out that the TAT 0 35 sequences spanning nt -147 to -168 encompassed putative recognition sequences for liver-enriched NFl Liver (a liver-enriched member of the NFlgene family, nt -163 to -168, 100% similarity with the TGG C / A A consensus) (38, 42) , and HNF2/HNF4/LFA1 (nt -156 to -161, 100% similarity with the TG G / A A / C CC consensus) (43) . Moreover, this search localized putative recognition sequences for the liver-enriched HNF1/LFB1 (nt -266 to -281, 85% similarity with the I^/AGTTAATNA/TTC/XNNCA consensus) (43, 44, reviewed in 45) and for the ubiquitous NF-Y (nt -70 to -77).
The ubiquitous NF-Y binds to and is a potent transcriptional activator of TAT 0 _j 5 The single retarded complex generated by radiolabeled ds-oligo II was specific and identical with both liver or spleen CNEs, arguing for the binding of a ubiquitous trans-acting factor ( Fig.  4; lanes 1,2,9,10 ). As expected from the presence of a 'AACC-AAT' homology within ds-oligo II, a bonafide NF-Y ds-oligo Table II ) was also an efficient competitor (Fig. 4, lanes 3,4 and  11,12 ). Ds-oligos VI and CTF/NF1 which possess CAAT homologies were poor competitors, whereas unrelated TATQ 35 ds-oligos (HI, IV, V) did not compete at all (not shown). Conversely, labeled NF-Y generated the same retardation pattern than ds-oligo II in the presence of liver and spleen CNEs and this gel shift was competed by 90-fold excesses of unlabelled NF-Y and ds-oligo n, but not by NF-Y m (Fig. 4 , lanes 5-8 and 13-16).
In the presence of liver CNEs, the transcriptional activity of TAT 0 35 was reduced by about 80% by 25 fold excesses of dsoligos II or NF-Y but not by Dm or NF-Ym (Fig. 7A) . Similar results were obtained in the presence of spleen CNEs: transcription from TAT 0 35 was inhibited by 64% by a 25-fold excess of ds-oligo n, but remained unchanged in the presence of Ilm (Fig.7A) Altogether, these results demonstrate that NF-Y (a) is a transacting factor which binds to the TAT 0 35 sequences spanning nt -57 to -85 and (b) behave as a potent, ubiquitous transcriptional activator of basal TAT0.35 promoter activity: it was almost equally potent in the presence of either liver or spleen CNEs.
The liver-enriched NFl L j Ver binds to and contributes to the transcriptional activity of TAT 0 3S The DNAse I footprint spanning nt -140 to -200 was initially arbitrarily split into two ds-oligos (V and VI), and preliminary gel shift and methylation interference experiments (GS-G and AG, unpublished; summarized in Table H ) led us to localize the 
DNA-protein interactions between nt -156 and -176 (ds-oligo vn).
Ds-oligo VII gave rise to tissue-specific retardation patterns (Fig. 5A, lanes 1, 3) . Two DNA-protein interactions were generated in the presence of liver CNEs. The broad, heavily labelled VII, band represented specific DNA-protein interactions since it was competed by a 90-fold molar excess of unlabelled ds-oligo VII (lane 2). On the contrary, a 90-fold excess of ds-oligo VII did not extinguish the faint, faster migrating gel shift VH 2 which therefore represents non-specific DNA-protein interaction (lane 2). Vn 2 was the main retarded band which was observed in the presence of spleen CNEs, and as was the case for liver CNEs, it was due to non-specific DNA-protein interactions (\anz 4). Depending on the spleen CNE, an additional faint slower migrating smear was inconsistently observed (lane 3).
Because binding sequences for the liver-enriched NFl Liver and HNF2 were contiguous within ds-oligo VH (cf. supra), we wondered whether one of these trans-acting factors was responsible for the liver-specific gel shift VH,. VQ, was not competed by unlabelled ds-oligos HNF2 at a 90-fold molar excess (Fig. 5B, lane 11 ) but was completely extinguished by a 90-fold excess of ds-oligo NFl L i ve r (site E of albumin promoter, 38) but not by its mutated counterpart (lanes 9, 10). Furthermore, incubation of 32 P-labelled ds-oligo NFl Liver with liver CNEs generated a retardation pattern identical to VH, (lane 12) and this gel shift was extinguished by a 30-fold molar excess of unlabelled ds-oligo VII (not shown). As expected, VI^ was not competed by unlabelled ds-oligos encompassing recognition sequences for the ubiquitous NF-Y and CTF/NF1 (lanes 6, 7) .
In the presence of liver CNEs, TAT 0 35 promoter activity was reduced to the same extent (52 and 59%) by 100-fold excesses of ds-oligo VII and NFl Liver respectively, but remained unchanged in the presence of a 100-fold molar excess of mutated NFl LlV er-However a slight inhibition of transcription (-20%) was observed in the presence of mutated ds-oligo VII at a 100-fold molar excess (Fig.7B) . By contrast, neither ds-oligo VH nor bona fide NFl Uver did abolish the slight transcriptional activity generated from TAT 035 in the presence of spleen CNEs (Fig.7B) .
Altogether, these results support the conclusion that NFl Llver binds to the TAT0.35 sequence spanning nt -156 to -176 and behave as a liver-specific transcriptional activator of promoter activity.
The liver-enriched HNF1 binds to and contributes to the transcriptional activity of TAT0. 35 Ds-oligo VIII generated a tissue-specific retardation pattern: the slower migrating gelshift (Vm,) was only observed in the presence of liver CNEs (Fig. 6, lanes 1, 10) , and encompassed a putative HNF1 recognition sequence. Accordingly, VIII, was extinguished by PE56 (a bona fide HNF1 binding site; 46) at a 3-fold molar excess, but not by its mutated form DS34 (46 ,  Table II ) or by ds-oligos which encompass a CCAAT homology (NF-Y, CTF/NF1 and ds-oligo VI from TAT a35 ) even at 90-fold molar excesses (Fig. 6, lanes 3-6 and data not shown) . Moreover, PE56-HNF1 complexes had the same mobility than VIIIi and were competed by unlabelled ds-oligo Vin (lane 8 and data not shown). An additional band (VIII3) was competed by PE56 but not by DS34 (lanes 3,4) . This band was also observed when spleen CNEs were incubated with radiolabeled ds-oligo VIII and PE56 (lanes 10,11) and may represent the interaction of v-HNFl homodimers with the HNF1 binding site.
In the presence of liver CNEs, TAT 035 promoter activity was reproducibly reduced by ~29% in the presence of a 100-fold molar excess of PE56) but remained unchanged in the presence either of DS34 or of a random ds-oligo (Table II; Fig. 7C ). By contrast, a 100-fold molar excess of PE56 did not modify TAT 0 35 promoter activity in the presence of spleen CNEs (Fig.  7C) .
Altogether, these results support the conclusion that the liverenriched trans-acting factor HNF1 may play a role in the liverspecific control of TAT 0 35 promoter activity, but suggested that its effect was moderate. However, since a CCAAT homology lies immediately 5' to the HNF1 homology (nt -290 to -282, Table II ), a functional cooperation between HNF1 and ubiquitous 'CCAAT-box' binding factor(s) cannot be excluded.
This speculation was supported by the following observations. First, ds-oligo VIII was much more efficient than PE56 in inhibiting in vitro transcription (-30% and 73% vs. 0% and 29% at 25-and 100-fold molar excesses, respectively) (Fig.  7C) . Second, when ds-oligo VIII was mutated within the CC-AAT homology (Vnim; Table II), its potency as an inhibitor of transcription (31%) was reduced to that of bona fide HNF1 (29%) when added at a 100-fold molar excess in the transcription mixture (Fig. 7C) . Third, wild type ds-oligo Vin but not dsoligo Vmm (100-fold molar excesses) was able to inhibit transcription from TAT0.35 in vitro ( -40% inhibition) in the presence of spleen CNEs (Fig. 7C) , consistant with the ubiquitous nature of the fra/u-acting factor interacting with the CAAT homology 5' to the HNF1 binding site.
In this connection, we have shown (i) that gel shift VH^ was completely extinguished by as few as a 3-fold excess of ds-oligo NF-Y, but was not competed by a 90-fold excess of NF-Ym and (ii) that VEl2b and bona fide NF-Y complexes displayed identical electrophoreticmobilities (Fig. 6, lanes 6, 7, 9 ). On the contrary, ds-oligo VIII was unable to extinguish the gel shift obtained with bona fide ds-oligo NF-Y or NFl Uver (Fig. 6, lanes  12-15) . Therefore, it seems unlikely that the higher efficiency of ds-oligo VIE in inhibiting in vitro transcription was due to the prevention of NF-Y and/or NFl Liver interaction with their cognate binding sequences on TAT O35 (nt -57 to -85 and nt -156 to -176, respectively). The overall decrease in basal expression, observed in H4II cells when TAT gene 5'-flanking sequences were shortened from -10 to -0.35 kb (-3.5-fold) (Table I) , was weaker than that obtained in FTO-2B hepatoma cells (110-fold) (26) . Noticeably, the deletion of the -3.6 Kb enhancer produced a > 50-fold decrease in activity in FTO-2B (26) but not in H4II cells (Table I and not shown). This may be due to hyperactivity of this enhancer in FTO-2B cells since forskolin treatment leads to weak cAMP induction of TATCAT[4289/+62] (1.5-fold) in these cells (22) , whereas cAMP induces TAT mRNA synthesis by 20-30 fold in the liver and in primary cultures of hepatocytes (14) .
DISCUSSION
The weakening of basal expression correlative to progressive deletion of TAT 5'-flanking sequences (Table I) points to a putative functional cooperation between promoter and enhancer elements in the maintenance of a high level of basal gene expression. Accordingly, when the -3.6 HS enhancer (target for Tse-1 mediated and cAMP reversion of extinction), and the liver-specific -11HS were tested immediately 5' to tk promoter sequences (ubiquitous) they were more efficient in 7AE27 (Tse 1 + ) microcell hybrids than in HTC hepatoma cells, although endogenous TAT gene expression was lower in the former cell line (26) . As stressed by these authors, this apparent discrepancy suggests the functional relevance of TAT promoter sequences in the liver-specific control of gene expression.
Our results both in transient transfection and in in vitro transcription further support the conclusion that TAT0.35 controls at least part of the liver-specificity of basal TAT gene expression. Indeed, the lack of chromatin structures and of stable epigenetic modifications (e.g. DNA methylation) (47) in our in vitro transcription assays (use of supercoiled plasmid DNA and of dialysed, histone-free CNEs) strengthens the involvement of the promoter sequences per se. . Factors binding to ds-oligos II, Vn and VUJ behave as transcriptional activators. Liver or spleen nuclear proteins (2.4 mg/ml) were preincubated at 0°C for 10 min in the absence or presence of a 25-or 100-fold molar excess of either wild type ds-oligos II, VII, VIII, NF-Y, NFl Liv<:r (NF1J, HNF1 (PE56), or of mutated Dm, Vllm, NFl L m, HNFlm (DS34), or of a random ds-oligo, as indicated above the lanes. pTAT and pAdML2 7O (30 and 10/jg/ml final concentration, respectively) were then added to each reaction mixture and transcription was allowed to proceed at 30°C for 45 min. Titration studies with: A, ds-oligo II and related ds-oligos; B, ds-oligo VTJ and related ds-oligos; C, ds-oligo VUJ and related ds-oligos. In each case, the TAT 0 35 transcriptional activity was computed relative to that of the ubiquitous AdML^o internal control. In many instances, the transcriptional activity of the reference promoter was slightly decreased in the presence of a 100-fold excess of competitor, probably owing to non-specific transcriptional inhibition (even observed with a randomly designed ds-oligo). % of TAT relative transcription = % of the TAT 0 35 transcriptional activity remaining in the presence of competitor ds-oligo (mean of 2 to 6 independent experiments; average SEM for all experiments: 7.54% of mean values; range: 3-9%, with the single exception of one experiment where it was 20%). M: molecular weight marker.
Thus, the liver-specific regulation of TAT gene expression as albumin (1, 48) , a-foetoprotein (49), or r antitrypsin and turns out to be regulatedthrough promoter as well as enhancer transthyretin (4, 50), and numerous constitutive and inducible sequences, as it is the case for other liver-specific genes such tissue-specific genes (see (51) and (52) for reviews). (44, 46) bound to the TAT O35 sequences spanning nt -161 to -147 and nt -281 to -266, respectively. No other region of the promoter was potentially able to interact with these two liver-enriched trans-acting factors (not shown).
The titration of NFl Ljver and HNF1 in the in vitro transcription mixture (competition experiments) demonstrated that they supported -60% and -30%, respectively, of the basal transcription sustained by TAT0.35 in the liver. Neither NFl Liver nor HNF1 recognition sequences did inhibit the slight transcription sustained by spleen CNEs, suggesting that these trans-acting factors act as positive transcriptional activators in TAT producing cells.
Nevertheless, the functional role of HNF1 per se seems moderate, consistent with previous observations that in C2 dedifferentiated hepatoma cells (a FaO derivative which does not express HNF1; 53), basal TAT gene expression was only slightly decreased and still inducible by glucocorticoids (54) . However, competition experiments in in vitro transcription suggested that in vivo, HNF1 may cooperate functionally with ubiquitous 'CC-AAT-box' binding factor(s) which bind to promoter sequences immediately 5'-to the HNF1 cw-element. Such functional interactions between trans-acimg factors have already been reported at the level of composite hormone response elements and in some instances, non-receptor factors drive the distinct physiologic effects exhibited by the same receptor molecule which bind to the same HRE (55-58; reviewed in 59).
Are NFl Liver recognition sequences putative targets for Jse-i-mediated repression of TAT gene promoter elements? 7ie-7-induced alterations of promoter-HS in 7AE27 cells (26) , suggest that Tse-1 could exert indirect effects [e.g. extinction of expression or alteration of the post-transcriptional modificationof the phosphorylation status for example-of liver-enriched trans-acting factor(s)]. In this connection, our observation (AG, unpublished) that identical gel shift patterns were obtained with ds-oligo VI in the presence of CNEs prepared either from hepatoma xfibroblast hybrid cells, which do not express the TAT gene, or from spleen supports this assumption. Since ds-oligo VI interacted with NFl Liver we speculate that extinction of NFl Liver expression might explain 7se-/-induced alteration of promoter-HS in 7AE27 cells.
TAT promoter sequences interact with ubiquitous <rans-acting factors, one of which is NF-Y Among the ubiquitous trans-acting factors binding to TAT promoter sequences, we have identified NF-Y (60,61) which binds to the 'AACCAAT' sequence localized between nt -71 and -77. It behaves as a ubiquitous transcriptional activator, equally active in the presence of liver and spleen extracts (62) , as in the mouse albumin promoter (39) . NF-Y interacts also, although weakly, with sequences localized 5'-to the HNF1 recognition sequence.
The TAT promoter thus appears as a modular transcriptional control unit being composed of an array of recognition sequences for both tissue-specific and ubiquitous trans-acting factors clustered around the initiation site. It is able to confer a liverspecific pattern of transcription, and thus appears to be involved in the overall liver-specific control of TAT gene expression.
